Jane Street
FDMT icon

Jane Street’s 4D Molecular Therapeutics FDMT Stock Holding History

Jane Street’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Buy
17,100
+900
+6% +$7.83K ﹤0.01% 10340
2025
Q4 		$122K Sell
16,200
-8,300
-34% -$84.2K ﹤0.01% 10071
2025
Q3 		$213K Buy
+24,500
New +$146K ﹤0.01% 9560
2024
Q2 		– Sell
-28,500
Closed -$908K – 9588
2024
Q1 		$908K Buy
+28,500
New +$727K ﹤0.01% 5595
2023
Q2 		– Sell
-20,700
Closed -$356K – 8918
2023
Q1 		$356K Buy
+20,700
New +$403K ﹤0.01% 6908

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jane Street's FDMT Position: Q1 2026 in Review

Jane Street reduced its 4D Molecular Therapeutics (FDMT) stake by 82% in Q1 2026, selling an estimated $1.61M and leaving 39,694 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #8755.

Jane Street first reported a position in FDMT in Q4 2022 and has held it in 13 quarters since. The position peaked at $2.8M in Q2 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Jane Street held 39,694 shares of 4D Molecular Therapeutics worth $370K as of Q1 2026.
  • Jane Street sold 185,209 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.61M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8755 holding.
  • Jane Street first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • Jane Street's 4D Molecular Therapeutics position peaked at $2.8M in Q2 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.